Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Bex

Showing results (11-20 of 331) with videos related to

Pageof 34
Sort By:
European Urology|June 2, 2014
Classification of renal cell carcinoma subtypes: there is more than meets the eyeAxel Bex
The Lancet. Oncology|February 16, 2015
Prognostic accuracy in second-line renal cancer therapyAxel Bex
European Urology|May 30, 2009
Editorial comment on: hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomesAxel Bex
European Urology|September 25, 2012
Interferon-α in combination with sorafenib: RAPSODY or requiem?Axel Bex
BJU International|September 15, 2012
Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombusAxel Bex
The Journal of Urology|October 30, 2019
Editorial CommentAxel Bex
European Urology|March 30, 2011
Targeted caval cytoreduction: solid foundations or shifting sands?Axel Bex, Noel Clarke
World Journal of Urology|February 27, 2013
Do targeted agents offer clinical benefit as presurgical therapy?Axel Bex, John Haanen
European Urology|June 13, 2024
EVEREST: Attempting the Summit with Adjuvant Everolimus To Treat High-risk Renal Cell Carcinoma After SurgeryJens Bedke, Axel Bex
Lancet (London, England)|July 31, 2023
TNM-based risk eligibility for adjuvant trials in renal cell carcinomaJens Bedke, Axel Bex
Pageof 34

Showing results (11-20 of 331) with videos related to

Sort By:
Pageof 34
European Urology|June 2, 2014
Classification of renal cell carcinoma subtypes: there is more than meets the eyeAxel Bex
The Lancet. Oncology|February 16, 2015
Prognostic accuracy in second-line renal cancer therapyAxel Bex
European Urology|May 30, 2009
Editorial comment on: hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomesAxel Bex
European Urology|September 25, 2012
Interferon-α in combination with sorafenib: RAPSODY or requiem?Axel Bex
BJU International|September 15, 2012
Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombusAxel Bex
The Journal of Urology|October 30, 2019
Editorial CommentAxel Bex
European Urology|March 30, 2011
Targeted caval cytoreduction: solid foundations or shifting sands?Axel Bex, Noel Clarke
World Journal of Urology|February 27, 2013
Do targeted agents offer clinical benefit as presurgical therapy?Axel Bex, John Haanen
European Urology|June 13, 2024
EVEREST: Attempting the Summit with Adjuvant Everolimus To Treat High-risk Renal Cell Carcinoma After SurgeryJens Bedke, Axel Bex
Lancet (London, England)|July 31, 2023
TNM-based risk eligibility for adjuvant trials in renal cell carcinomaJens Bedke, Axel Bex
Pageof 34